Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin in Severe COVID-19 (ANTICOVID)
NCT04808882Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tinzaparin in COVID-19 pneumonia (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: All-cause mortality at Day 28 and Number of days to clinical improvement at Day 28. Started Apr 2021; status: completed.
02
Drugs
tinzaparin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04808882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808882.